- The partnership centers around the large-scale manufacturing of drug-linker CL2A-SN-38, a crucial component of Immunomedics’ Sacituzumab Govitecan.
- The move comes under Immunomedics’ ongoing effort to invest & scale-up its supply capacity on a global level.
Immunomedics, a New Jersey-based pharmaceutical company, has reportedly announced that it has entered into a strategic manufacturing partnership agreement with British multinational specialty chemicals firm, Johnson Matthey.
Reports cite, the strategic partnership mainly revolves around the large-scale production of a drug-linker called CL2A-SN-38, which is a crucial component of Immunomedics’ Sacituzumab Govitecan, an antibody-drug conjugate.
According to a report by Nasdaq, the antibody-drug conjugate is presently under priority review by the United States Food & Drug Administration (U.S. FDA) for an expedited approval as a treatment for individuals suffering from a metastatic, triple negative form of breast cancer. The move comes under Immunomedics’ ongoing efforts to boost its supply capacity on a global level through partnerships with leading industry players in all components of the company’s supply chain.
The Chief Technology Officer of Immunomedics, Dr. Morris Rosenberg stated that the company is significantly scaling up its existing partnership with Johnson Matthey. Dr. Rosenberg further added that the deal is a testament to the company’s ongoing commitment to grow its supply-chain plan as it looks to broaden sacituzumab govitecan’s applicability to a plethora of solid cancer indications & expand to other markets across the world.
The Sector Chief Executive of Health at Johnson Matthey, Jason Apter stated that Immunomedics is one of the company’s biggest and most strategic partners and it is proud to rise up to the occasion and contribute its efforts to facilitate viable options of treatment for cancer patients and improve their lives in the process.
According to reports, the financial information related to the new strategic partnership agreement has not been disclosed yet.